Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Boland

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Seminars in Oncology|August 1, 2012
Locally advanced pancreatic cancerWilliam S Auriemma, Adam C Berger, Voichita Bar-Ad, et al.
British Journal of Cancer|August 3, 2016
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudyNamrata Vijayvergia, Patrick M Boland, Elizabeth Handorf, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.
European Journal of Cancer (Oxford, England : 1990)|May 6, 2021
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II studyZev A Wainberg, Tanios Bekaii-Saab, Patrick M Boland, et al.
JNCI Cancer Spectrum|May 2, 2024
A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancerPatrick M Boland, John M L Ebos, Kristopher Attwood, et al.
British Journal of Cancer|September 7, 2024
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trialPatrick M Boland, Sarbajit Mukherjee, Iman Imanirad, et al.
Investigational New Drugs|December 26, 2024
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancerPatrick M Boland, Heinz-Josef Lenz, Kristen K Ciombor, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel AdenocarcinomaKatrina S Pedersen, Nathan R Foster, Michael J Overman, et al.
American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|August 1, 2012
Locally advanced pancreatic cancerWilliam S Auriemma, Adam C Berger, Voichita Bar-Ad, et al.
British Journal of Cancer|August 3, 2016
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudyNamrata Vijayvergia, Patrick M Boland, Elizabeth Handorf, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.
European Journal of Cancer (Oxford, England : 1990)|May 6, 2021
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II studyZev A Wainberg, Tanios Bekaii-Saab, Patrick M Boland, et al.
JNCI Cancer Spectrum|May 2, 2024
A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancerPatrick M Boland, John M L Ebos, Kristopher Attwood, et al.
British Journal of Cancer|September 7, 2024
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trialPatrick M Boland, Sarbajit Mukherjee, Iman Imanirad, et al.
Investigational New Drugs|December 26, 2024
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancerPatrick M Boland, Heinz-Josef Lenz, Kristen K Ciombor, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel AdenocarcinomaKatrina S Pedersen, Nathan R Foster, Michael J Overman, et al.
American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.
Pageof 5